CL2013003795A1 - Pharmaceutical combination comprising an anti-erbb3 antibody and paclitaxel; use of the pharmaceutical combination to prepare a medicament useful for the treatment of refractory or platinum resistant gynecological cancer in a human patient. - Google Patents

Pharmaceutical combination comprising an anti-erbb3 antibody and paclitaxel; use of the pharmaceutical combination to prepare a medicament useful for the treatment of refractory or platinum resistant gynecological cancer in a human patient.

Info

Publication number
CL2013003795A1
CL2013003795A1 CL2013003795A CL2013003795A CL2013003795A1 CL 2013003795 A1 CL2013003795 A1 CL 2013003795A1 CL 2013003795 A CL2013003795 A CL 2013003795A CL 2013003795 A CL2013003795 A CL 2013003795A CL 2013003795 A1 CL2013003795 A1 CL 2013003795A1
Authority
CL
Chile
Prior art keywords
pharmaceutical combination
paclitaxel
refractory
prepare
treatment
Prior art date
Application number
CL2013003795A
Other languages
Spanish (es)
Inventor
William Kubasek
Victor Moyo
Joseph Pearlberg
Isabelle Tabah-Fisch
Gavin Macbeath
Original Assignee
Sanofi Sa
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Merrimack Pharmaceuticals Inc filed Critical Sanofi Sa
Publication of CL2013003795A1 publication Critical patent/CL2013003795A1/en

Links

CL2013003795A 2011-06-30 2013-12-30 Pharmaceutical combination comprising an anti-erbb3 antibody and paclitaxel; use of the pharmaceutical combination to prepare a medicament useful for the treatment of refractory or platinum resistant gynecological cancer in a human patient. CL2013003795A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161503342P 2011-06-30 2011-06-30
US201161529630P 2011-08-31 2011-08-31
FR1250860 2012-01-30

Publications (1)

Publication Number Publication Date
CL2013003795A1 true CL2013003795A1 (en) 2014-07-25

Family

ID=65657126

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003795A CL2013003795A1 (en) 2011-06-30 2013-12-30 Pharmaceutical combination comprising an anti-erbb3 antibody and paclitaxel; use of the pharmaceutical combination to prepare a medicament useful for the treatment of refractory or platinum resistant gynecological cancer in a human patient.

Country Status (1)

Country Link
CL (1) CL2013003795A1 (en)

Similar Documents

Publication Publication Date Title
GT201200313A (en) 5-FLUORO-1H-REPLACED PIRAZOLOPIRIDINES AND ITS USE
BR112014021103A8 (en) antibody, pharmaceutical composition, combination drug, DNA, method of treatment and use of antibody
CL2014003465A1 (en) Antibody that binds to the dimeric human epidermal growth factor receptor (hegfr); pharmaceutical composition comprising it; and use to treat cancer.
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
BR112015003332A2 (en) compound, pharmaceutical composition, use of the compound and method for treating a rorgammat-mediated disease or condition in a patient
BR112015003398A2 (en) compound, pharmaceutical composition, use of the compound and method for treating a rorgammat-mediated disease or condition in a patient
BR112015003397A2 (en) compound, pharmaceutical composition, use of the compound and method for treating a rorgammat-mediated disease or condition in a patient.
BR112015012644A2 (en) method for determining a cancer patient's need, cancer treatment method, pharmaceutical composition, use of a nucleic acid or antibody and kit;
BRPI1012116A2 (en) pharmaceutical composition for the treatment of heart disease
EA201991484A1 (en) MEDICINAL FORMS OF ENZALUTAMIDE
SV2010003581A (en) 4- (4-CIANO-2-TIOARIL) DIHYDROPIRIMIDINONES AND ITS USE
CL2012002606A1 (en) Pharmaceutical composition comprising (-) - carvone, (+) - carvone, trans-geraniol and at least one component chosen from essential oils for use in the treatment and prevention of viral diseases.
BR112013011480A2 (en) cancer treatment method, method of enhancing the therapeutic effectiveness of an anticancer drug, pmo1183 or a pharmaceutically acceptable salt thereof, use thereof and kit for use in cancer treatment
BR112014005091A2 (en) pharmaceutical composition for the treatment of cancer comprising interferon alpha conjugate
ES2542042R1 (en) Pharmaceutical compositions and use to prepare a drug for the treatment of obesity, related metabolic disorders and addiction to psychoactive substances
BRPI1006040A2 (en) use of pharmaceutical compositions, type of medical bandage, and type of medicine box
CL2015001202A1 (en) Compounds derived from oxazolidin-2-one-pyrimidine; pharmaceutical composition and combination and use in the treatment of cancer.
CL2013003324A1 (en) Composition comprising chemotherapy with paclitaxel and carboplatin and an anti-clusterine oligonucleotide; use of the composition for the treatment of a human patient suffering from lung cancer.
BR112013001297A2 (en) pharmaceutical compositions and their use and method of treating respiratory disease or condition
ES2446643R1 (en) Combined pharmaceutical compositions and their use to prepare a drug for the treatment of vertigo, motion sickness and vegetative-vascular dystonia
CL2012003322A1 (en) Compounds derived from substituted benzamide; pharmaceutical composition; and use in the treatment of cancer.
CL2014003325A1 (en) Compounds derived from difluoro-hexahydro-cyclopentaoxacinyls and difluoro-hexahydro-benzooxacinyls, bace 1 inhibitors; pharmaceutical composition; and its use in the treatment of diseases with elevated levels of beta-amyloid, such as Alzheimer's disease
BR112013014189A2 (en) pharmaceutical composition comprising transcinamaldehyde and its use in the treatment of infections
CL2014003525A1 (en) Pharmaceutical composition comprising fimasartan, hydrochlorothiazide and a binder; preparation procedure; its use in the treatment of hypertension.
BR112013016107A2 (en) dimeric molecule, cancer treatment method, pharmaceutical composition and kit for the diagnosis of an upar-mediated pathology or tumor